Dr. Califf Returns To US FDA: What To Do First?
Executive Summary
Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.
You may also be interested in...
US FDA Elevates Controlled Substances Coordinator To New Deputy CDER Director Role
The move should increase the visibility of the FDA’s wide-ranging, and widely criticized, opioid epidemic response.
US FDA Commissioner Califf Expects To Leave Post Following 2024 Elections
Outlining what changes he wants to see at the agency before he leaves, Califf also worries congressional inaction on the user fee reauthorization could affect hiring efforts.
Califf Appears To Set 2025 As End Of His Term As US FDA Commissioner
Outlining what changes he wants to see at the agency before he leaves, Califf also worries congressional inaction on the user fee reauthorization could affect hiring efforts.